综述:急性重症溃疡性结肠炎中英夫利西单抗的剂量优化
该综述系统检索2000至2016年MEDLINE及会议论文,评估英夫利西单抗药代动力学、给药策略与急性重症溃疡性结肠炎疾病行为关系的证据强度。共纳入76项研究,显示急性重症患者英夫利西单抗清除增加,部分队列研究提示剂量强化可能获益,但需前瞻性验证。
要点
- 急性重症溃疡性结肠炎患者英夫利西单抗清除增加,由总炎症负荷和药物漏入结肠腔驱动。
- 队列研究提示剂量强化对至少50%的急性重症患者有益,病例对照研究显示前3周增加1-2次输注可降低早期(3个月)结肠切除率高达80%。
- 上述数据需前瞻性验证,比较个体化剂量优化与常规剂量的随机对照试验是研究优先事项。
核心结论
- 非对照研究提示急性重症溃疡性结肠炎患者英夫利西单抗剂量优化可能获益。
- 比较个体化剂量优化策略与常规剂量的随机对照试验是研究优先事项。
研究设计与样本
- 系统检索MEDLINE和会议论文(2000至2016年),纳入描述急性重症溃疡性结肠炎英夫利西单抗药代动力学和/或剂量强化策略的随机对照试验、队列研究、横断面研究和病例对照研究。
- 共识别400篇文献,76项研究符合纳入标准。
主要发现
- 急性重症溃疡性结肠炎患者英夫利西单抗清除增加,由总炎症负荷和药物漏入结肠腔驱动。
- 若干队列研究提示英夫利西单抗剂量强化对至少50%的急性重症溃疡性结肠炎患者有益。
- 病例对照研究结果表明,治疗前3周内增加1-2次输注的强化给药方案可使早期(3个月)结肠切除率降低高达80%,但这些数据需要前瞻性验证。
局限性
- 支持剂量优化获益的研究为非对照研究。
- 病例对照研究数据需要前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen. AIM: To assess the strength of the current evidence for the relationship between infliximab pharmacokinetics, dosing strategies and disease behaviour in patients with acute severe UC. METHODS: We systematically searched MEDLINE and conference proceedings from 2000 to 2016 for relevant articles describing the pharmacokinetics of infliximab in acute severe UC and/or infliximab dose intensification strategies in acute severe UC. Eligible articles described randomised controlled trials, and cohort, cross-sectional, and case-controlled studies. RESULTS: Of 400 citations identified, 76 studies were eligible. Increased infliximab clearance occurs in patients with acute severe UC, and is driven by the total inflammatory burden and leakage of drug into the colonic lumen. Several cohort studies suggest that infliximab dose intensification is beneficial to at least 50% of acute severe UC patients and the results of case-controlled studies indicate that an intensified infliximab dosing regimen with 1-2 additional infusions in the first 3 weeks of treatment could reduce the early (3-month) colectomy rate by up to 80%, although these data require prospective validation. CONCLUSIONS: Uncontrolled studies suggest a benefit for infliximab dose optimisation in patients with acute severe UC. A randomised controlled trial in acute severe UC patients comparing a personalised infliximab dose-optimisation strategy with conventional dosing is a research priority.
引用
- Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 28074618. doi:10.1111/apt.13913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。